Peptide Library/Fat Loss & Metabolic/Cagrilintide

Cagrilintide

InvestigationalModerate Research

Also known as: NN9838 · AM833

A long-acting amylin analog that reduces appetite and enhances satiety, being developed in combination with semaglutide (CagriSema) for unprecedented weight loss.

Overview

Cagrilintide is a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells after meals. Amylin works synergistically with insulin to regulate post-meal glucose levels by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety through hypothalamic signaling. Cagrilintide has been engineered for once-weekly dosing and is being developed by Novo Nordisk both as a standalone therapy and in combination with semaglutide (branded as CagriSema). The combination of amylin and GLP-1 receptor agonism targets complementary appetite-regulation pathways, and early clinical data suggests CagriSema may produce weight loss exceeding 20-25% of body weight — approaching bariatric surgery outcomes.

Mechanism of Action

Agonist of the amylin receptor (calcitonin receptor/RAMP complex) in the area postrema and hypothalamus. Slows gastric emptying, suppresses postprandial glucagon secretion, and activates central satiety pathways. When combined with GLP-1 agonists, provides dual-pathway appetite suppression.

Key Benefits

Significant appetite reduction

Enhanced satiety after meals

Improved glycemic control

Synergistic weight loss with GLP-1 agonists

Reduced postprandial glucose spikes

Potential cardiovascular benefits

Potential Side Effects

Nausea (most common, usually transient)

Vomiting

Injection site reactions

Constipation or diarrhea

Common Stacks

This peptide is commonly combined with the following compounds for synergistic effects:

SemaglutideTirzepatideMetformin

Known Interactions

The following interactions have been documented for Cagrilintide. Always consult a healthcare professional before combining compounds.

Synergistic (1)

SemaglutideSynergistic

GLP-1 (semaglutide) + amylin analog (cagrilintide) targets two distinct satiety pathways. This combination (CagriSema) is in clinical trials showing superior weight loss.

View all compound interactions

Scientific References

Cagrilintide Plus Semaglutide in Obesity: A Phase 2 Trial

Enebo LB, Berthelsen KK, Kankam M, et al.

Nature Medicine (2021)

Once-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity

Lau DCW, Erichsen L, Francisco-Ziller N, et al.

Lancet (2021)

Quick Reference

Typical Dose

0.3mg-4.5mg

Frequency

1x daily

Route

Subcutaneous injection

Half-Life

~7 days (supports weekly dosing in clinical trials)

Cycle Length

1-2x weekly (split dose); as needed

FDA Status

Investigational — Phase 3 clinical trials ongoing. Not yet FDA approved. CagriSema (combination with semaglutide) in advanced development.

Need to calculate dosing?

Use our reconstitution calculator to determine exact syringe measurements.

Open Calculator

This information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.

Related Peptides in Fat Loss & Metabolic

Semaglutide

An FDA-approved GLP-1 receptor agonist that has revolutionized weight management, producing average weight loss of 15-17% of body weight in clinical trials.

Tirzepatide

A first-in-class dual GIP/GLP-1 receptor agonist that has demonstrated the most potent weight loss results of any pharmaceutical agent, averaging 20-26% body weight reduction.

AOD-9604

A modified fragment of human growth hormone (amino acids 176-191) that retains the fat-burning properties of HGH without its growth-promoting or diabetogenic effects.